Type I Gaucher disease, the subject of this article, was initially reported by Gaucher' in 1882 as a non-leukaemic splenic epithelioma. The biochemical defect, an autosomal recessively inherited lysosomal glucocerebrosidase enzyme deficiency, was delineated in 1965,2 3 and more recently the full length coding DNA sequence has been cloned and characterised. 4 Gaucher disease is conventionally classified into three types on the basis of neuronopathic manifestations and the natural course of the disorder.5 In contradistinction to type I Gaucher disease, types II and III have a primary neuronopathic infiltration with a progressive neurodegenerative course. The condition is acute in type II with death in early childhood, while type III is a subacute disorder with survival into adulthood.
Pathogenesis
The undegraded metabolite accumulates in cells of the monocyte macrophage system and hence the major clinical manifestations result from infiltration of the speen, liver, and bone marrow. Owing to the variable rate of substrate deposition, there is a wide spectrum of clinical involvement (figs 1 and 2) from severely affected infants to asymptomatic octogenarians. This unpredictable natural history complicates genetic counselling and patient management. 
Differential diagnosis
The diagnosis is confirmed by assaying the specific glucocerebrosidase enzyme in lymphocytes, platelets, or fibroblasts. Associated features include histologically typical Gaucher cells, particularly in liver, spleen, or bone marrow, raised serum acid phosphatase and angiotensin converting enzyme, and the characteristic radiographical features. These findings and the deficient enzyme activity distinguish type I Gaucher disease from the numerous inherited and acquired disorders causing hepatosplenomegaly and hypersplenism. Scattered storage cells histologically similar to Gaucher cells are found in some haematological conditions, such as leukaemia and thalassaemia, but are differentiated by the normal glucocerebrosidase activity in these disorders. and allogenic bone marrow transplantation. although potentially curative, is not justifiable in the majority of patients because the risks of the procedure outweigh the benefit offered to the mildly affected patient. Management is therefore aimed at the complications consequent on substrate accumulation.
HAEMATOL OGICAL Splenectomy reverses the pancytopenia, but there is considerable controversy concerning the progres-sion of the extrasplenic manifestations after this procedure. In the absence of prospective controlled trials, the role of splenectomy in the natural course of the disorder is uncertain. However, as there are no reliable predictive factors to determine which subjects are at later risk of orthopaedic complications, a conservative policy concerning splenectomy is advocated. This procedure should be delayed until there is life threatening pancytopenia or rarely, in young children, because of cardiorespiratory compromise. Furthermore, if indicated by these criteria, an attempt should be made to perform a partial splenectomy in the hope of providing a potential storehouse for substrate deposition.8 ORTHOPAEDIC Bone pain requires analgesia, with care to avoid acetylsalicylic acid and non-steroidal antiinflammatory agents if thrombocytopenia is present. Episodes of 'pseudo-osteomyelitis' resolve spontaneously over a period of a few days to about two weeks. Symptomatic therapy consists of bedrest and analgesia. It is particularly important to differentiate these episodes from pyogenic osteomyelitis to avoid unnecessary and potentially harmful bone drilling. The chronic sequelae of avascular necrosis of femoral heads with secondary osteoarthritis is managed with prosthetic joint replacement ( fig 5) with excellent long term results.9
Genetics
The condition is most prevalent among Ashkenazi Jews with an estimated carrier rate of 0-04 to 0-0810 compared to a carrier rate of 0 0044 in the Afrikaners of South Africa, the highest reported occurrence in a non-Jewish community.'t Heterozygotes are asymptomatic but enzyme assay is available for carrier detection and prenatal diganosis. 12
Future prospects
The isolation of a full length human glucocerebrosidase cDNA clone and its introduction with a retroviral vector into human cells in culture shows the potential for curative gene therapy for type I Gaucher disease. 13 Furthermore, this technology should facilitate the large scale production of pure glucocerebrosidase enzyme to allow more concerted attempts at enzyme replacement therapy, which has possibly failed so far because of the paucity of enzyme obtained by current purification techniques.
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